10 results on '"Bonthuis, Marjolein"'
Search Results
2. Associations of longitudinal height and weight with clinical outcomes in pediatric kidney replacement therapy: results from the ESPN/ERA Registry.
- Author
-
Bonthuis, Marjolein, Bakkaloglu, Sevcan A., Vidal, Enrico, Baiko, Sergey, Braddon, Fiona, Errichiello, Carmela, Francisco, Telma, Haffner, Dieter, Lahoche, Annie, Leszczyńska, Beata, Masalkiene, Jurate, Stojanovic, Jelena, Molchanova, Maria S., Reusz, George, Barba, Adela Rodriguez, Rosales, Alejandra, Tegeltija, Sanja, Ylinen, Elisa, Zlatanova, Galia, and Harambat, Jérôme
- Subjects
- *
KIDNEY disease treatments , *THERAPEUTICS , *REPORTING of diseases , *HUMAN growth , *BODY composition , *GRAFT rejection , *CONFIDENCE intervals , *RENAL replacement therapy , *PEDIATRICS , *TREATMENT effectiveness , *COMPARATIVE studies , *DESCRIPTIVE statistics , *RESEARCH funding , *BODY mass index , *PROPORTIONAL hazards models , *CHILDREN - Abstract
Background: Associations between anthropometric measures and patient outcomes in children are inconsistent and mainly based on data at kidney replacement therapy (KRT) initiation. We studied associations of height and body mass index (BMI) with access to kidney transplantation, graft failure, and death during childhood KRT. Methods: We included patients < 20 years starting KRT in 33 European countries from 1995–2019 with height and weight data recorded to the ESPN/ERA Registry. We defined short stature as height standard deviation scores (SDS) < –1.88 and tall stature as height SDS > 1.88. Underweight, overweight and obesity were calculated using age and sex-specific BMI for height-age criteria. Associations with outcomes were assessed using multivariable Cox models with time-dependent covariates. Results: We included 11,873 patients. Likelihood of transplantation was lower for short (aHR: 0.82, 95% CI: 0.78–0.86), tall (aHR: 0.65, 95% CI: 0.56–0.75), and underweight patients (aHR: 0.79, 95%CI: 0.71–0.87). Compared with normal height, patients with short and tall statures showed higher graft failure risk. All-cause mortality risk was higher in short (aHR: 2.30, 95% CI: 1.92–2.74), but not in tall stature. Underweight (aHR: 1.76, 95% CI: 1.38–2.23) and obese (aHR: 1.49, 95% CI: 1.11–1.99) patients showed higher all-cause mortality risk than normal weight subjects. Conclusions: Short and tall stature and being underweight were associated with a lower likelihood of receiving a kidney allograft. Mortality risk was higher among pediatric KRT patients with a short stature or those being underweight or obese. Our results highlight the need for careful nutritional management and multidisciplinary approach for these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Timing of renal replacement therapy does not influence survival and growth in children with congenital nephrotic syndrome caused by mutations in NPHS1: data from the ESPN/ERA-EDTA Registry
- Author
-
Hölttä, Tuula, Bonthuis, Marjolein, Van Stralen, Karlijn J., Bjerre, Anna, Topaloglu, Rezan, Ozaltin, Fatih, Holmberg, Christer, Harambat, Jerome, Jager, Kitty J., Schaefer, Franz, and Groothoff, Jaap W.
- Published
- 2016
- Full Text
- View/download PDF
4. Anemia in children following renal transplantation—results from the ESPN/ERA-EDTA Registry
- Author
-
Krischock, Leah A., van Stralen, Karlijn J., Verrina, Enrico, Tizard, E. Jane, Bonthuis, Marjolein, Reusz, György, Hussain, Farida K, Jankauskiene, Augustina, Novljan, Gregor, Spasojević-Dimitrijeva, Brankica, Podracka, Ludmila, Zaller, Vera, Jager, Kitty J., Schaefer, Franz, and on behalf of the ESPN/ERA-EDTA Registry
- Published
- 2016
- Full Text
- View/download PDF
5. Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease
- Author
-
Drube, Jens, Wan, Mandy, Bonthuis, Marjolein, Wuhl, Elke, Bacchetta, Justine, Santos, Fernando, Grenda, Ryszard, Edefonti, Alberto, Harambat, Jerome, Shroff, Rukshana, Tonshoff, Burkhard, Haffner, Dieter, Schnabel, D, Linglart, A, Rees, L, Cochat, P, Brauner, C, Renault, D, Romano, LN, Colling, G, Prytula, A, Leifheit-Nestler, M, Klaus, G, Schmitt, CP, Stabouli, S, Reusz, G, Verrina, E, Groothoff, J, Anton-Gamero, M, Petrosyan, E, Bakkaloglu, SA, Dursun, I, Booth, C, Aufricht, C, Vande Walle, J, Vondrak, K, Holtta, T, Ranchin, B, Fischbach, M, Stefanidis, C, Kyriakou, A, Printza, N, Paglialonga, F, Vidal, E, Allinovi, M, Jankauskiene, A, Zurowska, A, Faria, M Do Sameiro, Ariceta, G, Sartz, L, Bakkaloglu, S, Bayazit, AK, Duzova, A, Knops, N, Raees, A, Zieg, J, Pape, L, Melk, A, Dello, L, Guzzo, I, Ghio, L, Murer, L, Peruzzi, L, Bouts, A, Cornelissen, M, Lopez-Baez, Victor, Soylemezoglu, O, Topaloglu, R, Christian, M, Marks, S, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinicum, HUS Children and Adolescents, Helsinki University Hospital Area, Lastentautien yksikkö, Children's Hospital, and Çukurova Üniversitesi
- Subjects
0301 basic medicine ,PREPUBERTAL CHILDREN ,Pediatrics ,medicine.medical_treatment ,030232 urology & nephrology ,Growth disorders ,[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology ,0302 clinical medicine ,Quality of life ,QUALITY-OF-LIFE ,3123 Gynaecology and paediatrics ,Chronic kidney disease ,Child ,ADULT HEIGHT ,Human Growth Hormone ,Immunosuppression ,Urology & Nephrology ,DOUBLE-BLIND TRIAL ,3. Good health ,Growth hormone treatment ,Nephrology ,Child, Preschool ,medicine.symptom ,Life Sciences & Biomedicine ,medicine.medical_specialty ,CATCH-UP GROWTH ,Short stature ,03 medical and health sciences ,REPLACEMENT THERAPY ,Renal Dialysis ,medicine ,Humans ,Renal Insufficiency, Chronic ,SHORT STATURE ,Dialysis ,LONG-TERM GROWTH ,[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics ,Science & Technology ,Paediatric kidney disease ,PEDIATRIC-PATIENTS ,business.industry ,Consensus Statement ,Guideline ,medicine.disease ,3126 Surgery, anesthesiology, intensive care, radiology ,Kidney Transplantation ,Hormones ,Transplantation ,030104 developmental biology ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,CHRONIC-RENAL-FAILURE ,business ,Kidney disease - Abstract
Achieving normal growth is one of the most challenging problems in the management of children with chronic kidney disease (CKD). Treatment with recombinant human growth hormone (GH) promotes longitudinal growth and likely enables children with CKD and short stature to reach normal adult height. Here, members of the European Society for Paediatric Nephrology (ESPN) CKD–Mineral and Bone Disorder (MBD), Dialysis and Transplantation working groups present clinical practice recommendations for the use of GH in children with CKD on dialysis and after renal transplantation. These recommendations have been developed with input from an external advisory group of paediatric endocrinologists, paediatric nephrologists and patient representatives. We recommend that children with stage 3–5 CKD or on dialysis should be candidates for GH therapy if they have persistent growth failure, defined as a height below the third percentile for age and sex and a height velocity below the twenty-fifth percentile, once other potentially treatable risk factors for growth failure have been adequately addressed and provided the child has growth potential. In children who have received a kidney transplant and fulfil the above growth criteria, we recommend initiation of GH therapy 1 year after transplantation if spontaneous catch-up growth does not occur and steroid-free immunosuppression is not a feasible option. GH should be given at dosages of 0.045–0.05 mg/kg per day by daily subcutaneous injections until the patient has reached their final height or until renal transplantation. In addition to providing treatment recommendations, a cost-effectiveness analysis is provided that might help guide decision-making., This Evidence-Based Guideline developed by members of the European Society for Paediatric Nephrology CKD-MBD, Dialysis and Transplantation working groups presents clinical practice recommendations for the use of growth hormone in children with chronic kidney disease on dialysis and after renal transplantation.
- Published
- 2019
6. Hemodialysis vascular access and subsequent transplantation: a report from the ESPN/ERA-EDTA Registry.
- Author
-
Boehm, Michael, Bonthuis, Marjolein, Noordzij, Marlies, Harambat, Jérôme, Groothoff, Jaap W., Melgar, Ángel Alonso, Buturovic, Jadranka, Dusunsel, Ruhan, Fila, Marc, Jander, Anna, Koster-Kamphuis, Linda, Novljan, Gregor, Ortega, Pedro J., Paglialonga, Fabio, Saravo, Maria T., Stefanidis, Constantinos J., Aufricht, Christoph, Jager, Kitty J., and Schaefer, Franz
- Subjects
- *
AGE factors in disease , *CHRONIC kidney failure , *CONFIDENCE intervals , *REPORTING of diseases , *ARTERIOVENOUS fistula , *GLOMERULONEPHRITIS , *HEALTH services accessibility , *HEMODIALYSIS , *HEMOGLOBINS , *KIDNEY transplantation , *MEDICAL referrals , *MEDICAL practice , *ORGAN donors , *PEDIATRICS , *REGRESSION analysis , *RISK assessment , *VASCULITIS , *LOGISTIC regression analysis , *PROPORTIONAL hazards models , *CENTRAL venous catheters , *PATIENTS' attitudes , *DESCRIPTIVE statistics , *ODDS ratio - Abstract
Background: Current guidelines advocate use of arteriovenous fistula (AVF) over central venous catheter (CVC) for children starting hemodialysis (HD). European data on current practice, determinants of access choice and switches, patient survival, and access to transplantation are limited.Methods: We included incident patients from 18 European countries who started HD from 2000 to 2013 for whom vascular access type was reported to the ESPN/ERA-EDTA Registry. Data were evaluated using descriptive statistics, logistic and Cox regression models, and cumulative incidence competing risk analysis.Results: Three hundred ninety-three (55.1%) of 713 children started HD with a CVC and were more often females, younger, had more often an unknown diagnosis, glomerulonephritis, or vasculitis, and lower hemoglobin and height-SDS at HD initiation. AVF patients were 91% less likely to switch to a second access, and two-year patient survival was 99.6% (CVC, 97.2%). Children who started with an AVF were less likely to receive a living donor transplant (adjusted HR, 0.30; 95% CI, 0.16-0.54) and more likely to receive a deceased donor transplant (adjusted HR, 1.50; 95% CI, 1.17-1.93), even after excluding patients who died or were transplanted in the first 6 months.Conclusions: CVC remains the most frequent type of vascular access in European children commencing HD. Our results suggest that the choice for CVC is influenced by the time of referral, rapid onset of end-stage renal disease, young age, and an expected short time to transplantation. The role of vascular access type on the pattern between living and deceased donation in subsequent transplantation requires further study. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. Adult Height in Patients with Advanced CKD Requiring Renal Replacement Therapy during Childhood
- Author
-
Harambat, Jérôme, Bonthuis, Marjolein, van Stralen, Karlijn J., Ariceta, Gema, Battelino, Nina, Bjerre, Anna, Jahnukainen, Timo, Leroy, Valérie, Reusz, György, Sandes, Ana R., Sinha, Manish D., Groothoff, Jaap W., Combe, Christian, Jager, Kitty J., Verrina, Enrico, Schaefer, Franz, Szabó, Tamás, Other departments, Medical Informatics, APH - Amsterdam Public Health, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Other Research, Paediatric Nephrology, and ACS - Amsterdam Cardiovascular Sciences
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Multivariate analysis ,Time Factors ,Adolescent ,Epidemiology ,medicine.medical_treatment ,Urinary system ,Critical Care and Intensive Care Medicine ,Klinikai orvostudományok ,urologic and male genital diseases ,Risk Factors ,medicine ,Prevalence ,Humans ,In patient ,Renal replacement therapy ,Registries ,Child ,Normal range ,Growth Disorders ,Transplantation ,business.industry ,Final height ,Age Factors ,Infant, Newborn ,Infant ,Orvostudományok ,Original Articles ,Adult height ,female genital diseases and pregnancy complications ,Body Height ,Large cohort ,Europe ,Renal Replacement Therapy ,Treatment Outcome ,Nephrology ,Child, Preschool ,Multivariate Analysis ,Disease Progression ,Linear Models ,Kidney Failure, Chronic ,Female ,business ,adult height ,advanced CKD ,renal replacement during childhood - Abstract
Summary Background and objectives Growth and final height are of major concern in children with ESRD. This study sought to describe the distribution of adult height of patients who started renal replacement therapy (RRT) during childhood and to identify determinants of final height in a large cohort of RRT children. Design, setting, participants, & measurements A total of 1612 patients from 20 European countries who started RRT before 19 years of age and reached final height between 1990 and 2011 were included. Linear regression analyses were performed to calculate adjusted mean final height SD score (SDS) and to investigate its potential determinants. Results The median final height SDS was −1.65 (median of 168 cm in boys and 155 cm in girls). Fifty-five percent of patients attained an adult height within the normal range. Adjusted for age at start of RRT and primary renal diseases, final height increased significantly over time from −2.06 SDS in children who reached adulthood in 1990–1995 to −1.33 SDS among those reaching adulthood in 2006–2011. Older age at start of RRT, more recent period of start of RRT, cumulative percentage time on a functioning graft, and greater height SDS at initiation of RRT were independently associated with a higher final height SDS. Patients with congenital anomalies of the kidney and urinary tract and metabolic disorders had a lower final height than those with other primary renal diseases. Conclusions Although final height remains suboptimal in children with ESRD, it has consistently improved over time.
- Published
- 2013
8. Outcomes of renal replacement therapy in boys with prune belly syndrome: findings from the ESPN/ERA-EDTA Registry.
- Author
-
Yalcinkaya, Fatos, Bonthuis, Marjolein, Erdogan, Beyza Doganay, van Stralen, Karlijn J., Baiko, Sergey, Chehade, Hassib, Maxwell, Heather, Montini, Giovanni, Rönnholm, Kai, Sørensen, Søren Schwartz, Ulinski, Tim, Verrina, Enrico, Weber, Stefanie, Harambat, Jérôme, Schaefer, Franz, Jager, Kitty J., and Groothoff, Jaap W.
- Subjects
- *
TREATMENT effectiveness , *PRUNE belly syndrome , *REPORTING of diseases , *HEMODIALYSIS , *KIDNEY diseases , *PEDIATRICS , *TIME , *TRANSPLANTATION of organs, tissues, etc. , *THERAPEUTICS - Abstract
Background: As outcome data for prune belly syndrome (PBS) complicated by end-stage renal disease are scarce, we analyzed characteristics and outcomes of children with PBS using the European Society for Pediatric Nephrology/European Renal Association-European Dialysis and Transplant Association (ESPN/ERA-EDTA) Registry data. Methods: Data were available for 88 male PBS patients aged <20 years who started renal replacement therapy (RRT) between 1990 and 2013 in 35 European countries. Patient characteristics, survival, and transplantation outcomes were compared with those of male patients requiring RRT due to congenital obstructive uropathy (COU) and renal hypoplasia or dysplasia (RHD). Results: Median age at onset of RRT in PBS was lower [7.0; interquartile range (IQR) 0.9-12.2 years] than in COU (9.6; IQR: 3.0-14.1 years) and RHD (9.4; IQR: 2.7-14.2 years). Unadjusted 10-year patient survival was 85% for PBS, 94% for COU, and 91% for RHD. After adjustment for country, period, and age, PBS mortality was similar to that of RHD but higher compared with COU [hazard ratio (HR) 1.96, 95% confidence interval (CI) 1.03-3.74]. Seventy-four PBS patients (84%) received a first kidney transplant after a median time on dialysis of 8.4 (IQR 0.0-21.1) months. Outcomes with respect to time on dialysis before transplantation, chance of receiving a first transplant within 2 years after commencing RRT, and death-censored, adjusted risk of graft loss were similar for all groups. Conclusions: This study in the largest cohort of male patients with PBS receiving RRT to date demonstrates that outcomes are comparable with other congenital anomalies of the kidney and urinary tract, except for a slightly higher mortality risk compared with patients with COU. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
9. Lessons learned from the ESPN/ERA-EDTA Registry.
- Author
-
Harambat, Jérôme, Bonthuis, Marjolein, Groothoff, Jaap, Schaefer, Franz, Tizard, E., Verrina, Enrico, Stralen, Karlijn, and Jager, Kitty
- Subjects
- *
TREATMENT of chronic kidney failure , *ANEMIA , *CARDIOVASCULAR diseases risk factors , *CHRONIC kidney failure , *REPORTING of diseases , *EXPERIMENTAL design , *HUMAN growth , *KIDNEY diseases , *NUTRITION , *PEDIATRICS , *RARE diseases , *THERAPEUTICS , *COMORBIDITY , *DISEASE incidence , *DISEASE prevalence ,CHRONIC kidney failure complications - Abstract
End-stage renal disease (ESRD) in children is a medically challenging condition. Due to its rarity and special features, methodologically sound collaborative studies are required. In 2007, a new European registry of pediatric renal replacement therapy (RRT), the ESPN/ERA-EDTA Registry, was launched. In recent years, the Registry has provided comprehensive data on incidence, prevalence, patient characteristics, RRT modalities, and mortality in pediatric ESRD, along with relevant insights into cardiovascular risk, anemia, nutrition and growth, transplantation outcomes, and rare diseases. In this review, we describe the study design and structure underlying the ESPN/ERA-EDTA Registry, summarize the major research findings from more than 20 publications, and discuss current limitations and the future challenges to overcome. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
10. Mortality risk disparities in children receiving chronic renal replacement therapy for the treatment of end-stage renal disease across Europe: an ESPN-ERA/EDTA registry analysis.
- Author
-
Chesnaye, Nicholas C., Schaefer, Franz, Bonthuis, Marjolein, Holman, Rebecca, Baiko, Sergey, Baskın, Esra, Bjerre, Anna, Cloarec, Sylvie, Cornelissen, Elisabeth A. M., Espinosa, Laura, Heaf, James, Stone, Rosário, Shtiza, Diamant, Zagozdzon, Ilona, Harambat, Jérôme, Jager, Kitty J., Groothoff, Jaap W., van Stralen, Karlijn J., and ESPN/ERA-EDTA Registry Committee
- Subjects
- *
KIDNEY diseases , *KIDNEY transplantation , *PEDIATRICS , *CHILD mortality , *PUBLIC health , *MACROECONOMICS , *THERAPEUTICS - Abstract
Background: We explored the variation in country mortality rates in the paediatric population receiving renal replacement therapy across Europe, and estimated how much of this variation could be explained by patient-level and country-level factors.Methods: In this registry analysis, we extracted patient data from the European Society for Paediatric Nephrology/European Renal Association-European Dialysis and Transplant Association (ESPN/ERA-EDTA) Registry for 32 European countries. We included incident patients younger than 19 years receiving renal replacement therapy. Adjusted hazard ratios (aHR) and the explained variation were modelled for patient-level and country-level factors with multilevel Cox regression. The primary outcome studied was all-cause mortality while on renal replacement therapy.Findings: Between Jan 1, 2000, and Dec 31, 2013, the overall 5 year renal replacement therapy mortality rate was 15·8 deaths per 1000 patient-years (IQR 6·4-16·4). France had a mortality rate (9·2) of more than 3 SDs better, and Russia (35·2), Poland (39·9), Romania (47·4), and Bulgaria (68·6) had mortality rates more than 3 SDs worse than the European average. Public health expenditure was inversely associated with mortality risk (per SD increase, aHR 0·69, 95% CI 0·52-0·91) and explained 67% of the variation in renal replacement therapy mortality rates between countries. Child mortality rates showed a significant association with renal replacement therapy mortality, albeit mediated by macroeconomics (eg, neonatal mortality reduced from 1·31 [95% CI 1·13-1·53], p=0·0005, to 1·21 [0·97-1·51], p=0·10). After accounting for country distributions of patient age, the variation in renal replacement therapy mortality rates between countries increased by 21%.Interpretation: Substantial international variation exists in paediatric renal replacement therapy mortality rates across Europe, most of which was explained by disparities in public health expenditure, which seems to limit the availability and quality of paediatric renal care. Differences between countries in their ability to accept and treat the youngest patients, who are the most complex and costly to treat, form an important source of disparity within this population. Our findings can be used by policy makers and health-care providers to explore potential strategies to help reduce these health disparities.Funding: ERA-EDTA and ESPN. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.